Evidence map›Paper›PMID 37298751›Full record

ArticleMolecules (Basel, Switzerland)2023

Tandem LC-MS Identification of Antitubercular Compounds in Zones of Growth Inhibition Produced by South African Filamentous Actinobacteria.

Daniel J Watson, Lubbe Wiesner, Tlhalefo Matimela, Denzil Beukes, Paul R Meyers

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel J WatsonDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town 7700, South Africa.ORCID 0000-0002-3217-3286
Lubbe WiesnerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town 7700, South Africa.ORCID 0000-0002-9070-8699
Tlhalefo MatimelaDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town 7700, South Africa.ORCID 0000-0002-0906-6722
Denzil BeukesSchool of Pharmacy, University of the Western Cape, Bellville 7535, South Africa.ORCID 0000-0002-0223-2660
Paul R MeyersDepartment of Molecular and Cell Biology, University of Cape Town, Cape Town 7700, South Africa.ORCID 0000-0003-1894-5910

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel antitubercular compounds are urgently needed to combat drug-resistant

Indexed as

ActinobacteriaMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAgarAntitubercular AgentsChromatography, LiquidHumansMicrobial Sensitivity TestsSouth AfricaTandem Mass SpectrometryAgarAntitubercular Agentsantitubercularfilamentous actinobacteriaHPLC-MS/MSnatural productszone of inhibition

Identifiers

PMID37298751
PMCPMC10254512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.